Pharmaceuticals, Biotechnology & Life Sciences

Avadel Pharmaceuticals PLC shares hit $21.50 as shareholders approve a strategic acquisition, with major investors like Vanguard and State Street filing 1%+ stake disclosures under the Irish Takeover Panel Act, signaling a potential market shift for…

Fate Therapeutics boosts talent retention with new employee awards, underscoring its role in advancing stem‑cell regenerative medicine while navigating biotech valuation challenges.

Ionis Pharmaceuticals doubles Tryngolza sales forecast to $2 billion, positioning itself for robust 2026 growth amid a strong antisense oligonucleotide launch and strategic partnerships.

Lexicon Pharmaceuticals updates its biopharma pipeline at J.P. Morgan Healthcare, highlighting breakthrough treatments for diabetes, obesity, and cancer—showing strong innovation despite current financial volatility.

Lexaria Bioscience’s 2025 breakthrough in oral GLP‑1 delivery with DehydraTECH™ positions the company to capture a booming market, unlocking new therapeutic avenues for investors.

Vericel Corp projects $276 M revenue in 2025, led by 23 % Q4 MACI growth, showing strong traction in regenerative medicine and a $1.95 B market cap.

Avita Medical’s board reshuffle and modest stock rebound hint at untapped potential in its burn and wound‑care therapies, yet the stock remains heavily discounted.

BriaCell Therapeutics shares volatile 2025 results, with its BriaVax breast‑cancer vaccine driving investor interest and a negative P/E yet strong market cap.

Vaxart’s pioneering oral flu vaccine tech sparks biotech buzz and investor interest—learn how gut‑stimulated immunity could reshape flu prevention and boost the company’s growth.

Explore Terns Pharmaceuticals’ latest moves in liver‑cancer drug development and market trends, plus key 2026 conference insights and investor outlook.